Chloroquine interferes with dengue‐2 virus replication in U937 cells

Farias, Kléber Juvenal Silva; Machado, Paula Renata Lima; Junior, Renato Ferreira de Almeida; Aquino, Ana Alice de; Fonseca, Benedito Antônio Lopes da

doi:10.1111/1348-0421.12154

Cited by 66 publications

(56 citation statements)

References 36 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This potentially interferes with the fusion of viral and endosomal membranes. In vitro studies showed that chloroquine inhibited DENV1 replication in THP cells overexpressing DC-SIGN and DENV2 replication in U937 and Vero cells [32][33][34]. Furthermore, chloroquine was shown to reduce viremia in monkeys infected with DENV2 [36].…”

Section: Drug Repurposing For Dengue Therapymentioning

confidence: 99%

Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus

Anasir

Ramanathan

Poh

2020

Viruses

View full text Add to dashboard Cite

Dengue virus (DENV) presents a significant threat to global public health with more than 500,000 hospitalizations and 25,000 deaths annually. Currently, there is no clinically approved antiviral drug to treat DENV infection. The envelope (E) glycoprotein of DENV is a promising target for drug discovery as the E protein is important for viral attachment and fusion. Understanding the structure and function of DENV E protein has led to the exploration of structure-based drug discovery of antiviral compounds and peptides against DENV infections. This review summarizes the structural information of the DENV E protein with regards to DENV attachment and fusion. The information enables the development of antiviral agents through structure-based approaches. In addition, this review compares the potency of antivirals targeting the E protein with the antivirals targeting DENV multifunctional enzymes, repurposed drugs and clinically approved antiviral drugs. None of the current DENV antiviral candidates possess potency similar to the approved antiviral drugs which indicates that more efforts and resources must be invested before an effective DENV drug materializes.

show abstract

Section: Drug Repurposing For Dengue Therapymentioning

confidence: 99%

Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus

Anasir

Ramanathan

Poh

2020

Viruses

View full text Add to dashboard Cite

show abstract

“…Dengue virus and WNV replication has also been reported to be blocked by CQ in cell culture (Boonyasuppayakorn et al, 2014;Farias et al, 2014). A recent study has demonstrated the efficacy of CQ in the prophylactic and therapeutic treatment of Aotus monkeys inoculated with DENV (Farias et al, 2015).…”

Section: Chloroquine and Its Analogsmentioning

confidence: 99%

Drug repurposing for new, efficient, broad spectrum antivirals

2019

View full text Add to dashboard Cite

Emerging viruses are a major threat to human health. Recent outbreaks have emphasized the urgent need for new antiviral treatments. For several pathogenic viruses, considerable efforts have focused on vaccine development. However, during epidemics infected individuals need to be treated urgently. High-throughput screening of clinically tested compounds provides a rapid means to identify undiscovered, antiviral functions for wellcharacterized therapeutics. Repurposed drugs can bypass part of the early cost and time needed for validation and authorization. In this review we describe recent efforts to find broad spectrum antivirals through drug repurposing. We have chosen several candidates and propose strategies to understand their mechanism of action and to determine how resistance to antivirals develops in infected cells.

show abstract

“…In vitro, chloroquine appears as a versatile bioactive agent reported to possess antiviral activity against RNA viruses as diverse as rabies virus [16], poliovirus [17], HIV [12,[18][19][20], hepatitis A virus [21,22], hepatitis C virus [23], influenza A and B viruses [24][25][26][27], influenza A H5N1 virus [28], Chikungunya virus [29][30][31], Dengue virus [32,33], Zika virus [34], Lassa virus [35], Hendra and Nipah viruses [36,37], Crimean-Congo hemorrhagic fever virus [38] and Ebola virus [39], as well as various DNA viruses such as hepatitis B virus [40] and herpes simplex virus [41].The antiviral properties of chloroquine described in vitro have sometimes been confirmed during treatment of virus-infected patients but have not always been reproduced in clinical trials depending on the disease, the concentration of chloroquine used, the duration of treatment and the clinical team in charge of the trial. Regarding coronaviruses, the potential therapeutic benefits of chloroquine were notably reported for SARS-CoV-1 [11,42].…”

Section: Antiviral Role Of Chloroquinementioning

confidence: 99%

Therapeutic Preferences for Coronavirus 2(SARS-CoV-2) Patients

Mustafa¹

2020

Preprint

View full text Add to dashboard Cite

Background: Modern researches have focused the attention towards the potential advantage of chloroquine, a broadly used antimalarial drug, in the treatment of patients infected by the novel appeared coronavirus (SARS-CoV-2). Chloroquine/hydroxychloroquine has been frequently used in treating SARS-CoV-2 infection. Which is useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients. The scientific community should consider this information in light of previous experiments with Chloroquine/hydroxychloroquine in the field of antiviral research. Methods: In the view of current situation efforts of international health professionals have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease. It is mandatory to investigate the possible effect of chloroquine/hydroxychloroquine against SARS-CoV-2. Since this molecule was previously described as a potent inhibitor of most coronaviruses, including SARS-CoV-1. Preliminary trials of chloroquine repurposing in the treatment of COVID-19 in China have been encouraging, leading to several new trials. Here we discuss the possible mechanisms of chloroquine interference with the SARS-CoV-2 replication cycle.Results: Chloroquine has been shown to be capable of inhibiting the in vitro replication of several coronaviruses. Recent publications support the hypothesis that chloroquine/hydroxychloroquine can improve the clinical outcome of patients infected by SARS-CoV-2.

show abstract

Chloroquine interferes with dengue‐2 virus replication in U937 cells

Cited by 66 publications

References 36 publications

Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus

Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus

Drug repurposing for new, efficient, broad spectrum antivirals

Therapeutic Preferences for Coronavirus 2(SARS-CoV-2) Patients

Contact Info

Product

Resources

About